These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26815524)

  • 1. PSMA-PSA clones controlled by full Akt phosphorylation (T308+,S473+) recapitulate molecular features of human prostate cancer.
    Ben Jemaa A; Bouraoui Y; Sallami S; Banasr A; Nouira Y; Horchani A; Oueslati R
    Tunis Med; 2015; 93(8-9):556-64. PubMed ID: 26815524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PSA-PSMA profiles and their impact on sera PSA levels and angiogenic activity in hyperplasia and human prostate cancer.
    Ben Jemaa A; Bouraoui Y; Sallami S; Banasr A; Nouira Y; Oueslati R
    Pathol Biol (Paris); 2014 Jun; 62(3):129-36. PubMed ID: 24745345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PSMA/PSA ratio evaluated by immunohistochemistry may improve diagnosis of prostate cancer.
    Jemaa AB; Bouraoui Y; Sallami S; Banasr A; Nouira Y; Oueslati R
    J Immunoassay Immunochem; 2014; 35(1):48-59. PubMed ID: 24063616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine profiling identifies an interaction of IL-6 and IL-1α to drive PSMA-PSA prostate clones.
    Jemaa AB; Bouraoui Y; Rais NB; Nouira Y; Oueslati R
    Immunobiology; 2016 Dec; 221(12):1424-1431. PubMed ID: 27451139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular distribution and heterogeneity of Psa and Psma expression in normal, hyperplasia and human prostate cancer.
    Ben Jemaa A; Bouraoui Y; Sallami S; Banasr A; Nouira Y; Horchani A; Oueslati R
    Tunis Med; 2013 Jul; 91(7):458-63. PubMed ID: 24008878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insight into the heterogeneity of prostate cancer through PSA-PSMA prostate clones: mechanisms and consequences.
    Ben Jemaa A; Bouraoui Y; Oueslati R
    Histol Histopathol; 2014 Oct; 29(10):1263-80. PubMed ID: 24788382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the biological features of prostate cancer with (PSA+, PSMA+) profile according to RKIP.
    Ben Jemaa A; Bouraoui Y; Sallami S; Nouira Y; Oueslati R
    Biomed Res Int; 2013; 2013():409179. PubMed ID: 23991415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies.
    Ben Jemaa A; Bouraoui Y; Sallami S; Banasr A; Ben Rais N; Ouertani L; Nouira Y; Horchani A; Oueslati R
    J Exp Clin Cancer Res; 2010 Dec; 29(1):171. PubMed ID: 21189143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of PSA, PSMA and hK2 mRNA in peripheral blood of prostate cancer patients and its clinical implications.
    Xu T; Chen X; Wang XF; Hou SK; Zhu JC; Zhang XD; Huang XB
    Beijing Da Xue Xue Bao Yi Xue Ban; 2004 Apr; 36(2):164-8. PubMed ID: 15100735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High expression of PSM-E correlated with tumor grade in prostate cancer: a new alternatively spliced variant of prostate-specific membrane antigen.
    Cao KY; Mao XP; Wang DH; Xu L; Yuan GQ; Dai SQ; Zheng BJ; Qiu SP
    Prostate; 2007 Dec; 67(16):1791-800. PubMed ID: 17929272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profile of NF-κBp(65/NFκBp50) among prostate specific antigen sera levels in prostatic pathologies.
    Bouraoui Y; Ben Jemaa A; Rodriguez G; Ben Rais N; Fraile B; Paniagua R; Sellemi S; Royuela M; Oueslati R
    Pathol Biol (Paris); 2012 Oct; 60(5):301-5. PubMed ID: 21889270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel regulation of PSMA and PSA expression by Q640X AR in 22Rv1 and LNCaP prostate cancer cells.
    Ben Jemaa A; Sallami S; Céraline J; Oueslati R
    Cell Biol Int; 2013 May; 37(5):464-70. PubMed ID: 23418075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients.
    Kurek R; Nunez G; Tselis N; Konrad L; Martin T; Roeddiger S; Aumüller G; Zamboglou N; Lin DW; Tunn UW; Renneberg H
    Clin Cancer Res; 2004 Sep; 10(17):5808-14. PubMed ID: 15355910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate specific membrane antigen knockdown impairs the tumorigenicity of LNCaP prostate cancer cells by inhibiting the phosphatidylinositol 3-kinase/Akt signaling pathway.
    Guo Z; Lai Y; Du T; Zhang Y; Chen J; Bi L; Lin T; Liu H; Wang W; Xu K; Jiang C; Han J; Zhang C; Dong W; Huang J; Huang H
    Chin Med J (Engl); 2014; 127(5):929-36. PubMed ID: 24571890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel Role of Prostate-Specific Membrane Antigen in Telomere Stability in Prostate Cancer Cells.
    Reddy V; Hwang C; Reddy GP; Kim SH
    Mol Cancer Res; 2023 Nov; 21(11):1176-1185. PubMed ID: 37477641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.
    Kristiansen I; Stephan C; Jung K; Dietel M; Rieger A; Tolkach Y; Kristiansen G
    Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28555048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients.
    Schmittgen TD; Teske S; Vessella RL; True LD; Zakrajsek BA
    Int J Cancer; 2003 Nov; 107(2):323-9. PubMed ID: 12949815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
    Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
    Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ad5/35E1aPSESE4: A novel approach to marking circulating prostate tumor cells with a replication competent adenovirus controlled by PSA/PSMA transcription regulatory elements.
    Hwang JE; Joung JY; Shin SP; Choi MK; Kim JE; Kim YH; Park WS; Lee SJ; Lee KH
    Cancer Lett; 2016 Mar; 372(1):57-64. PubMed ID: 26723876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer.
    Xiang B; Dong DW; Shi NQ; Gao W; Yang ZZ; Cui Y; Cao DY; Qi XR
    Biomaterials; 2013 Sep; 34(28):6976-91. PubMed ID: 23777916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.